Single-Agent Topotecan as First-Line Chemotherapy in Women with Metastatic Breast Cancer: Final Results of Eastern Cooperative Oncology Group Trial E8193

Although tolerable, this dose and schedule of topotecan has limited activity in unselected patients with breast cancer even as first-line therapy. Identification of potential predictive markers of response and toxicity is encouraged before considering further studies of topotecan and camptothecin analogues in breast cancer.